Atypical HUS: time to take stock of current guidelines and outcome measures?

Abstract

European guidelines for the assessment and management of atypical HUS were written in 2009. Since then our understanding of this group of diseases has advanced. Evidence is emerging that eculizumab, a monoclonal antibody inhibiting C5 activation, is effective, and potentially superior to current treatment with plasmapheresis. The evidence base for the… (More)
DOI: 10.1007/s00467-013-2423-x

Topics

  • Presentations referencing similar topics